Navigation Links
EntreMed Reports Second Quarter 2008 Financial Results
Date:8/6/2008

EntreMed to Conduct Update Call on Tuesday, August 12, 2008

ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported financial results for the three and six-month periods ending June 30, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

The Company reported a net loss for the second quarter of 2008 of ($9.6 million), or ($0.11) per share. This compares with a net loss of ($7.9 million), or ($0.10) per share, for the same period last year. For the first six months of 2008 the reported net loss was ($17.9 million), or ($0.22) per share as compared to ($15.6 million), or ($0.19) per share for 2007. The 2008 net loss for the three and six-month periods include a non-cash charge of $2.0 million, which represents a purchase price adjustment milestone triggered by the dosing of the first patient in a clinical trial for ENMD-2076, the lead molecule in our Aurora kinase program acquired from Miikana Therapeutics in January 2006.

The Company did not report any revenues for the first six months of 2008, although the Company believes that it will record royalty revenues in excess of $7 million on sales of Thalomid(R) by Celgene in the third and fourth quarters of 2008. As of June 30, 2008, EntreMed had cash and short-term investments of approximately $36 million.

Dane Saglio, EntreMed Chief Financial Officer, commented on the second quarter results, "During the second quarter of 2008, we recorded a $2.0 million non-cash charge resulting from the Company's dec
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
2. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
3. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
4. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
5. EntreMed Receives Nasdaq Deficiency Notice
6. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
7. EntreMed Announces 2008 Corporate and Clinical Program Priorities
8. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
9. EntreMed to Present at BIO CEO and Investor Conference
10. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
11. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)...  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company ... addressing major unmet medical needs using RNA-targeted technologies, ... Allowance from the United States Patent and Trademark ... for the treatment of fibrosis. The patent covers ...
(Date:1/14/2014)... January 13, 2014 Bob Hainsey, a ... than 20 years in the industry, has joined ... Hainsey will serve as the society’s Science and Technology ... join SPIE as our Technology Strategist, further strengthening the ...
(Date:1/14/2014)... 2014 Independent publisher Bitingduck Press, with ... Canada, has big ideas for 2014 in production and ... are to produce high-quality, low-cost, DRM-free ebooks and to ... , The first major development will be bookstore ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2
... , Many ... their application in cell culture and fermentation. ... antibody or antigen from a sample (from,serum, for example) by adding the corresponding antigen ... adherence of substances in solution or suspension, ...
... By J. Doyle, L. Johnstone and L. Cottis, ... AGEN Biomedical Ltd. Queensland, Australia, ,http://www.agen.com.au , ... The CelliGen Plus immobilized-bed perfusion was investigated as ... to in vivo production. This,system best represented a production facility that was easy ...
... , ... This Application Report is one ... 110,benchtop fermentor/bioreactor system. The modular,BioFlo 110 is offered with an extensive ... of cultures, including mammalian, insect,plant, yeast and bacterial cells. Complete kits are ...
Cached Biology Technology:Glossary for The BioPharm Guide to Fermentation and Cell Culture 2Glossary for The BioPharm Guide to Fermentation and Cell Culture 3Glossary for The BioPharm Guide to Fermentation and Cell Culture 4Glossary for The BioPharm Guide to Fermentation and Cell Culture 5Glossary for The BioPharm Guide to Fermentation and Cell Culture 6Glossary for The BioPharm Guide to Fermentation and Cell Culture 7Glossary for The BioPharm Guide to Fermentation and Cell Culture 8Glossary for The BioPharm Guide to Fermentation and Cell Culture 9Glossary for The BioPharm Guide to Fermentation and Cell Culture 10Glossary for The BioPharm Guide to Fermentation and Cell Culture 11Glossary for The BioPharm Guide to Fermentation and Cell Culture 12Glossary for The BioPharm Guide to Fermentation and Cell Culture 13Glossary for The BioPharm Guide to Fermentation and Cell Culture 14Glossary for The BioPharm Guide to Fermentation and Cell Culture 15Glossary for The BioPharm Guide to Fermentation and Cell Culture 16Gram Quantities of MAb Produced with Simple Bioreactor in Serum-Free Perfusion Culture Replacing Ascitic Fluid Production 2Hybridoma Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor 2Hybridoma Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor 3Hybridoma Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor 4Hybridoma Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor 5Hybridoma Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor 6
(Date:4/20/2014)... people with Down syndrome have a heightened risk of ... been able to explain why. Now, a team ... between the two conditions. , In a study posted ... the researchers track the genetic chain of events that ... cellular havoc that occurs in ALL. Their findings ...
(Date:4/18/2014)... A survey of emergency contraceptive pills in Peru ... were either of substandard quality or falsified. Many ... had the wrong active ingredient. One batch had ... detect the fake drugs, researchers at the Georgia ... mass spectrometry to quickly assess suspected counterfeit drugs ...
(Date:4/18/2014)... feeding a world population predicted to reach 9 ... to conservation that considers human-altered landscapes such as ... the natural habitat that supports it might be ... at least three-quarters of the land surface is ... vulnerable to human-caused impacts such as climate change. ...
Breaking Biology News(10 mins):Dana-Farber researchers uncover link between Down syndrome and leukemia 2Dana-Farber researchers uncover link between Down syndrome and leukemia 3Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4
... WI, NOVEMBER 17, 2008 Global land use patterns ... urban stormwater management. Traditional stormwater management focuses on ... generally does little to restore the hydrologic cycle ... with low permeability. The lack of infiltration opportunities ...
... Mellon University,s Robotics Institute have received a total of ... Agriculture (USDA) to build automated farming systems. One is ... but both are designed to improve fruit quality and ... autonomous robotic vehicles or at fixed sites within the ...
... team of researchers led by investigators at the Albert ... that certain commonly-prescribed medications may have the unintended consequence ... finding could alter the way doctors prescribe migraine medicines. ... Headache , the Einstein-led study of more than ...
Cached Biology News:Urban trees enhance water infiltration 2Carnegie Mellon developing automated systems to enable precision farming of apples, oranges 2Carnegie Mellon developing automated systems to enable precision farming of apples, oranges 3Overuse of narcotics and barbiturates may make migraine worse 2
...
... matrix proteins (NMPs) make up the internal structural ... such functions as DNA replication, RNA synthesis, and ... been shown to be highly insoluble in ... death releases soluble nuclear matrix proteins that can ...
Request Info...
... AC is the easiest to ... and is provided with liquid ... and rinse bottles. The integrated ... and priming functions guarantee excellent ...
Biology Products: